The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases

BACKGROUND: Despite the development of several FLT3 inhibitors that have improved outcomes in patients with FLT3-mutant acute myeloid leukemias (AML), drug resistance is frequently observed, which may be associated with the activation of additional pro-survival pathways such as those regulated by BT...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Guopan, Zhang, Weiguo, Zhang, Hongying, Ly, Charlie, Basyal, Mahesh, Rice, William G., Andreeff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980215/
https://www.ncbi.nlm.nih.gov/pubmed/36865133
http://dx.doi.org/10.21203/rs.3.rs-2570204/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980215/
https://www.ncbi.nlm.nih.gov/pubmed/36865133
http://dx.doi.org/10.21203/rs.3.rs-2570204/v1

Ejemplares similares